2005
DOI: 10.1248/bpb.28.1192
|View full text |Cite
|
Sign up to set email alerts
|

A New Retinoid-Like Compound That Activates Peroxisome Proliferator-Activated Receptors and Lowers Blood Glucose in Diabetic Mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2010
2010
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 43 publications
(9 citation statements)
references
References 16 publications
0
9
0
Order By: Relevance
“…PPAR- γ is a critical target of a number of insulin-sensitizing drugs [35]. Treatment with EBN significantly increased the transcriptional activity of PPAR- γ in HEK293 cells (Figure 2(a)).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…PPAR- γ is a critical target of a number of insulin-sensitizing drugs [35]. Treatment with EBN significantly increased the transcriptional activity of PPAR- γ in HEK293 cells (Figure 2(a)).…”
Section: Resultsmentioning
confidence: 99%
“…PPAR- γ participates in glucose uptake, and PPAR- γ agonists increase the sensitivity of insulin receptors [35]. In addition to thiazolidinedione, a PPAR- γ agonist that is used clinically, naturally occurring ingredients or compounds have also been used as PPAR- γ agonists to significantly improve insulin resistance [3, 18, 19].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The expression of PPARγ and RXRα which have been recognized as crucial players in the pathogenesis of atherosclerosis was associated with a more pronounced disease progression in patients with advanced carotid atherosclerotic lesions [72]. More targeted modulation of function through ligands design has been proposed as a strategy to possibly overcome observed rexinoids side effects that have limited the use of these compounds in the treatment of metabolic diseases [21,73]. It is exciting options that the therapy of metabolic diseases originating from the synthesis of heterodimer-selective rexinoids for PPARγ/RXRα combining with PPARγ agonists.…”
Section: Modulation Of Permissive Ppar/rxr Heterodimersmentioning
confidence: 99%